Leading Infectious Disease Physician Joins Pall as Medical Director.

EAST HILLS, N.Y. -- Joseph S. Cervia M.D., a leading infectious disease expert and pediatrician, joins Pall Corporation (NYSE:PLL) as Medical Director. Dr. Cervia's prior posts were Director of the Comprehensive HIV Care and Research Center of the Long Island Jewish Medical Center (LIJ); attending

physician, Division of Infectious Diseases in the Department of Medicine at LIJ; attending pediatrician, Division of Infectious Diseases at Schneider Children's Hospital and Professor of Clinical Medicine and Clinical Pediatrics at Albert Einstein College of Medicine. He also served as the chairman of the New York State Department of Health AIDS Institute Committee for the Care of Children and Adolescents.

Dr. Cervia assumes global responsibility for Pall Corporation's broad array of products, services and relationships in the medical arena including research, product development, marketing, quality control and regulatory.

"Dr. Cervia's extensive and impressive accomplishments support Pall's mission to improve patient care world wide," says Roberto Perez, President of Pall Life Sciences. "His clinical experience and judgment will benefit our entire Life Sciences operations and the myriad customers we serve."

Dr. Cervia was formerly an associate professor at Cornell University Medical College and at the State University of New York, Health Sciences Center at Stony Brook. He is board certified by the American Academy of HIV Medicine, The American Board of Pediatrics and the American Board of Internal Medicine as well as the Specialty Boards of Adult and Pediatric Infectious Diseases. He has been recognized in America's Registry of Outstanding Professionals and the Guide to America's Top Pediatricians.

Dr. Cervia has been a principal investigator in scores of clinical studies in the areas of AIDS, infectious diseases, immunology and pediatrics. He is a prolific author and a frequent lecturer. Dr. Cervia earned his M.D. degree from New York Medical College in 1984.

Pall Medical is a leading supplier to blood centers and hospitals around the world. In September, Pall reported fiscal 2004 sales of $1.77 billion. This includes almost $700 million in sales generated by its Life Sciences business.

As part of the Company's ongoing commitment to enhance the safety of the world's blood supply, it provides leukocyte reduction filters and enhanced Bacterial Detection Systems to test platelets for contamination. Bacterial contamination of platelets is the leading infectious cause of transfusion-transmitted fatalities.

The Company is also developing the Leukotrap(R) Affinity Prion Reduction Filter in response to increasing evidence that vCJD, the human form of Mad Cow diseases, may be transmitted by donor blood. It is anticipated that this unique product will be launched early in 2005.

Pall also provides the Pall-Aquasafe(TM) Water Filter, Ultipor(R) Breathing System Filters and Posidyne(R) Intravenous Filter Sets, which are on the front lines of defense against hospital-acquired infections. The prevention of nosocomial infections is a top priority for U.S. and international health care systems.

About Pall

Pall Corporation is the leader in the rapidly growing fields of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, transfusion medicine, semiconductors, municipal drinking water, aerospace and broad industrial markets. Total revenues are $1.77 billion. The Company headquarters are in East Hills, New York with operations in about 40 countries. Visit Pall at www.pall.com.

This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current Company expectations and are subject to risk and uncertainties, which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to: fluctuations in foreign currency exchange rates; regulatory approval and market acceptance of new technologies; changes in product mix and product pricing and in interest rates and cost of raw materials; the Company's success in enforcing its patents and protecting its proprietary products and manufacturing techniques and its ability to achieve the savings anticipated from its cost reduction initiatives; global and regional economic conditions and legislative, regulatory and political developments; and domestic and international competition in the Company's global markets. Additional information regarding these and other factors is available on the Web at www.pall.com and is included in the Company's reports filed with the U.S. Securities and Exchange Commission. Copies of such reports can be obtained, without charge, at www.sec.gov.

Editor's Note:

A Photograph of Dr. Cervia can be found at www.pall.com/pressroom.